Jonathan C. Cohen

Active 1987–2024

105
Papers
43,025
Citations
90
h-index
105
i10-index

Citations

Citations per year for Jonathan C. Cohen1955: 1 citations1972: 1 citations1985: 1 citations1987: 1 citations1988: 3 citations1989: 4 citations1990: 5 citations1991: 13 citations1992: 6 citations1993: 12 citations1994: 23 citations1995: 27 citations1996: 30 citations1997: 27 citations1998: 35 citations1999: 46 citations2000: 38 citations2001: 35 citations2002: 95 citations2003: 165 citations2004: 222 citations2005: 256 citations2006: 362 citations2007: 358 citations2008: 532 citations2009: 460 citations2010: 555 citations2011: 557 citations2012: 541 citations2013: 575 citations2014: 553 citations2015: 579 citations2016: 554 citations2017: 575 citations2018: 470 citations2019: 1,393 citations2020: 1,658 citations2021: 1,533 citations2022: 1,085 citations2023: 745 citations2024: 1,151 citations2025: 574 citations2026: 30 citations1956–1971: no citations, so these years are not shown1973–1984: no citations, so these years are not shown1986: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,483 citing papers, 28.2% of this breakdownChina: 1,380 citing papers, 8.7% of this breakdownUnited Kingdom: 1,086 citing papers, 6.8% of this breakdownItaly: 865 citing papers, 5.5% of this breakdownGermany: 769 citing papers, 4.8% of this breakdownCanada: 651 citing papers, 4.1% of this breakdownNetherlands: 525 citing papers, 3.3% of this breakdownFrance: 515 citing papers, 3.3% of this breakdownJapan: 442 citing papers, 2.8% of this breakdownAustralia: 401 citing papers, 2.5% of this breakdownSweden: 386 citing papers, 2.4% of this breakdownSpain: 337 citing papers, 2.1% of this breakdown
0%28.2%Other 25.5%

Fields

  • Medicine69.9%
  • Biochemistry, Genetics and Molecular Biology24.5%
  • Immunology and Microbiology1.4%
  • Neuroscience0.8%
  • Agricultural and Biological Sciences0.7%
  • Nursing0.7%
  • Other2%

Topics

  • Liver Disease Diagnosis and Treatment12%
  • Lipoproteins and Cardiovascular Health5.3%
  • Diabetes, Cardiovascular Risks, and Lipoproteins4.8%
  • Diet, Metabolism, and Disease4.2%
  • Cholesterol and Lipid Metabolism3.9%
  • Lipid metabolism and disorders3.3%
  • Other66.5%

Coauthors

All papers

Open in search
  1. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

    Authors: , , , , , , , , - Nature Genetics 2008 cited by 3,385

  2. Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease

    Authors: , , , - New England Journal of Medicine 2006 cited by 3,205

  3. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Scott M. Damrauer, Daniel J. Rader, Brian Zambrowicz, William C. Olson, Andrew Murphy, Ingrid B. Borecki, Alan R. Shuldiner, Jeffrey G. Reid, John D. Overton, George D. Yancopoulos, Helen H. Hobbs, Jonathan C. Cohen, Omri Gottesman, Tanya M. Teslovich, Aris Baras, Tooraj Mirshahi, Jesper Gromada, Frederick E. Dewey - New England Journal of Medicine 2018 cited by 805

  4. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease

    Authors: , , , , , , , , - Nature Genetics 2014 cited by 1,204

  5. Human Fatty Liver Disease: Old Questions and New Insights

    Authors: , , - Science 2011 cited by 2,088

  6. Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity

    Authors: , , , , , , , - Hepatology 2004 cited by 3,664

  7. Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis

    Authors: , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2019 cited by 283

  8. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci

    Authors: , , , , , - Nature Genetics 2017 cited by 396

  9. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9

    Authors: , , , , , - Nature Genetics 2005 cited by 1,387

  10. PNPLA3, CGI‐58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice

    Authors: , , , , - Hepatology 2019 cited by 216

  11. The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation

    Authors: , , , - Hepatology 2017 cited by 287

  12. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance

    Authors: , , , , , , , , , , , , , , , - Journal of Lipid Research 2020 cited by 202

  13. Exome Sequencing,ANGPTL3Mutations, and Familial Combined Hypolipidemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2010 cited by 778

  14. A Sequence Variation (I148M) in PNPLA3 Associated with Nonalcoholic Fatty Liver Disease Disrupts Triglyceride Hydrolysis

    Authors: , , , , , , , - Journal of Biological Chemistry 2009 cited by 600

  15. Hepatic TM6SF2 Is Required for Lipidation of VLDL in a Pre-Golgi Compartment in Mice and Rats

    Authors: , , , , , , , , - Cellular and Molecular Gastroenterology and Hepatology 2021 cited by 109

  16. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis

    Authors: , , , , , , , - Hepatology 2014 cited by 374

  17. Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation

    Authors: , , , , , , , - Journal of Biological Chemistry 2007 cited by 784

  18. Atypical angiopoietin-like protein that regulates ANGPTL3

    Authors: , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2012 cited by 456

  19. A feed-forward loop amplifies nutritional regulation of PNPLA3

    Authors: , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2010 cited by 382

  20. ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance

    Authors: , , , , , , , , , , , , , - Journal of Lipid Research 2017 cited by 206

  21. GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5

    Authors: , , , , , , , , , , , , - Nature 2003 cited by 1,242

  22. Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins

    Authors: , , , , - Journal of Biological Chemistry 2016 cited by 223

  23. PCSK9: a convertase that coordinates LDL catabolism

    Authors: , , - Journal of Lipid Research 2008 cited by 631

  24. Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound Heterozygote

    Authors: , , , , , , , - The American Journal of Human Genetics 2006 cited by 633